Pharmaceutical - Zealand Pharma

Filter

Current filters:

Zealand Pharma

Popular Filters

Zealand Pharma achieves milestone in Sanofi collaboration on LixiLan

Zealand Pharma achieves milestone in Sanofi collaboration on LixiLan

16-01-2014

Denmark’s Zealand Pharma says it has achieved a milestone under its collaboration with French drug…

DiabetesFinancialLixiLanLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Sanofi’s Lyxumia meets primary endpoint in Ph IIIb diabetes study

Sanofi’s Lyxumia meets primary endpoint in Ph IIIb diabetes study

05-12-2013

Results of a 24-week Phase IIIb clinical study showed that French drug major Sanofi’s diabetes drug…

DiabetesLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Lyxumia plus basal insulin lowers blood sugar, latest data show

Lyxumia plus basal insulin lowers blood sugar, latest data show

05-10-2013

Sanofi has announced new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia…

DiabetesLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Sanofi temporarily pulls lixisenatide NDA in USA

12-09-2013

French drug major Sanofi (Euronext: SAN) this morning (September 12) announced its decision to withdraw…

DiabeteslixisenatideLyxumiaNorth AmericaPharmaceuticalRegulationSanofiZealand Pharma

Zealand and Lilly to work together on type 2 diabetes and obesity therapies

29-08-2013

Denmark's Zealand Pharma (Nasdaq OMX: ZEAL) has announced an exclusive peptide drug R&D collaboration…

DiabetesEli LillyGlobalPharmaceuticalResearchZealand Pharma

Helsinn and Zealand to advance elsiglutide for chemotherapy-induced diarrhea prevention

28-05-2013

Privately-held Swiss pharmaceutical group Helsinn and its partner, Denmark-based Zealand Pharma A/S (Nasdaq:…

elsiglutideGastro-intestinalsHelsinnOncologyPharmaceuticalResearchZealand Pharma

US FDA accepts Sanofi's NDA for diabetes drug lixisenatide

19-02-2013

The US Food and Drug Administration has accepted for review French drug major Sanofi's (Euronext: SAN)…

DiabeteslixisenatideNorth AmericaPharmaceuticalRegulationSanofiZealand Pharma

Sanofi files for Japanese approval of diabetes drug Lyxumia

11-06-2012

French drug major Sanofi (Euronext: SAN), has submitted a marketing authorization application for lixisenatide…

Asia-PacificDiabeteslixisenatideLyxumiaPharmaceuticalRegulationSanofiZealand Pharma

Abbott Labs acquires drug candidate from Action Pharma

04-05-2012

US health care group Abbott Laboratories (NYSE: ABT) and Action Pharma A/S, a privately-owned company…

Abbott LaboratoriesAction PharmaLicensingNephrology and HepatologyPharmaceuticalZealand Pharma

$20 million lixisenatide milestone for Zealand Pharma

13-02-2012

Danish peptide drug discovery firm Zealand Pharma (Nasdaq OMX Copenhagen: ZEAL) says it will receive…

DiabetesFinanciallixisenatideLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Sanofi files for EU approval of Lyxumia, a type-2 diabetes agent partnered with Zealand Pharma

04-11-2011

Danish drug discovery firm Zealand Pharma (Nasdaq OMX: ZEAL.CO), says that its partner, French drug major…

DiabetesFinancialLyxumiaPharmaceuticalRegulationSanofiZealand Pharma

Sanofi presents positive results with Lyxumia and Lantus in type 2 diabetes at EASD meeting

13-09-2011

French drug major Sanofi (Euronext: SAN) has reported positive results from the GetGoal-F1 study with…

DiabetesLantusLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Back to top